{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:02:49Z","timestamp":1790193769844,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.psychres.2019.112584","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T11:25:11Z","timestamp":1569583511000},"page":"112584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The effect of bezafibrate in preventing glucolipid abnormalities induced by the antipsychotic risperidone"],"prefix":"10.1016","volume":"281","author":[{"given":"Xian-Yu","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2019.112584_bib0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12933-016-0332-6","article-title":"Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial","volume":"15","author":"Arbel","year":"2016","journal-title":"Cardiovasc. Diabetol"},{"issue":"1","key":"10.1016\/j.psychres.2019.112584_bib0002","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40291-013-0017-8","article-title":"Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy: is there a role for folate?","volume":"17","author":"Burghardt","year":"2013","journal-title":"Mol. Diagn. Ther."},{"issue":"3","key":"10.1016\/j.psychres.2019.112584_bib0003","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/jvim.14701","article-title":"Therapy of canine hyperlipidemia with bezafibrate","volume":"31","author":"De Marco","year":"2017","journal-title":"J. Vet. Intern. Med."},{"issue":"3","key":"10.1016\/j.psychres.2019.112584_bib0004","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.molmet.2016.12.007","article-title":"Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic Tallyho mice","volume":"6","author":"Franko","year":"2017","journal-title":"Mol. Metab."},{"issue":"9","key":"10.1016\/j.psychres.2019.112584_bib0005","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.bbadis.2017.05.019","article-title":"Bezafibrate prevents mitochondrial dysfunction, antioxidant system disturbance, glial reactivity and neuronal damage induced by sulfite administration in striatum of rats: implications for a possible therapeutic strategy for sulfite oxidase deficiency","volume":"1863","author":"Grings","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis. Dis."},{"issue":"1","key":"10.1016\/j.psychres.2019.112584_bib0006","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4158\/EP161445.RA","article-title":"Triglycerides, atherosclerosis, and cardiovascular outcome studies: focus on omega-3 fatty acids","volume":"23","author":"Handelsman","year":"2017","journal-title":"Endocr. Pract."},{"issue":"10","key":"10.1016\/j.psychres.2019.112584_bib0007","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1248\/cpb.c18-00346","article-title":"Synthesis and in vivo lipid-lowering activity of novel imidazoles-5-carboxamide derivatives in triton-wr-1339-induced hyperlipidemic wistar rats","volume":"66","author":"Jasim","year":"2018","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"issue":"5","key":"10.1016\/j.psychres.2019.112584_bib0008","first-page":"390","article-title":"Chinese guidelines on prevention and treatment of dyslipidemia in adults","volume":"35","year":"2007","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"11","key":"10.1016\/j.psychres.2019.112584_bib0009","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1194\/jlr.M076901","article-title":"Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial","volume":"58","author":"Koopal","year":"2017","journal-title":"J. Lipid. Res."},{"issue":"4","key":"10.1016\/j.psychres.2019.112584_bib0010","first-page":"322","article-title":"Cognitive change in schizophrenic patients with concomitant metabolism syndrome","volume":"19","author":"Li","year":"2010","journal-title":"Chin. J. Behav. Med. Brain. Sci."},{"issue":"2","key":"10.1016\/j.psychres.2019.112584_bib0011","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2013a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"1A","key":"10.1016\/j.psychres.2019.112584_bib0012","doi-asserted-by":"crossref","first-page":"33J","DOI":"10.1016\/S0002-9149(99)00356-2","article-title":"Insulin resistance and systemic hypertension","volume":"84","author":"Osei","year":"1999","journal-title":"Am. J. Candiol."},{"issue":"1","key":"10.1016\/j.psychres.2019.112584_bib0013","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12035-018-1074-0","article-title":"Bezafibrate prevents glycine-induced increase of antioxidant enzyme activities in rat striatum","volume":"56","author":"Parmeggiani","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"4","key":"10.1016\/j.psychres.2019.112584_bib0014","first-page":"231","article-title":"Investigation and analysis of blood lipid in 730 patients with chronic schizophrenia","volume":"23","author":"Peng","year":"2010","journal-title":"Sichuan Ment. Health"},{"issue":"5","key":"10.1016\/j.psychres.2019.112584_bib0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4239\/wjd.v7.i5.74","article-title":"Use of fibrates in the metabolic syndrome: a review","volume":"7","author":"Shipman","year":"2016","journal-title":"World J. Diabetes"},{"issue":"1","key":"10.1016\/j.psychres.2019.112584_bib0016","first-page":"21","article-title":"Relationship among antipsychotic therapy and body weight and blood lipid etc.","volume":"18","author":"Wang","year":"2008","journal-title":"J. Clin. Psychiat."},{"issue":"1","key":"10.1016\/j.psychres.2019.112584_bib0017","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/hmg\/ddy343","article-title":"Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia","volume":"28","author":"Waskowicz","year":"2019","journal-title":"Hum. Mol. Genet."},{"issue":"12","key":"10.1016\/j.psychres.2019.112584_bib0018","first-page":"79","article-title":"Effect of bezafibrate on hyperlipidemia and blood glucose in schizophrenic patients","volume":"17","author":"Wei","year":"2014","journal-title":"Chin. J. Pract. Nerv. Dis."},{"issue":"5","key":"10.1016\/j.psychres.2019.112584_bib0019","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1055\/s-2006-940056","article-title":"Dyslipidemia and schizophrenia","volume":"34","author":"Wetterling","year":"2007","journal-title":"Psychiatr. Prax."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178119311916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178119311916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:37:24Z","timestamp":1759037844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178119311916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":19,"alternative-id":["S0165178119311916"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2019.112584","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of bezafibrate in preventing glucolipid abnormalities induced by the antipsychotic risperidone","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2019.112584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112584"}}